Li-Chun Lu

Li-Chun Lu

Auto-generated profile, based on publicly available information

Li-Chun Lu

Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2016 in Liver Cancer
Verified
Journal Article
Open access
PDF file
LLLi-Chun Lu
Li-Chun Lu
CHChih-Hung Hsu
Chih-Hung Hsu
CHChiun Hsu
Chiun Hsu
LCLi-Tzong Chen
Li-Tzong Chen
Tumor heterogeneity in hepatocellular carcinoma (HCC), such as that found in second primary tumors after curative treatment, synchronous multifocal tumors of different clonality, or intratumor heterogeneity, poses severe challenges for the development and administration of systemic molecular targeted therapies. Various methodologies, including historical DNA ploidy analysis, integrated hepatitis B virus DNA analysis, DNA fingerprinting, and next-generation sequencing technologies, are used to explore tumor heterogeneity in HCC. It is estimated that 30%-60% of recurrent or metastatic tumors harbor clones different from the primary tumor, 22%-79% of synchronous tumors vary clonally, and 12%-66% of single tumors contain intratumor heterogeneity. Substantial intertumor and intratumor heterogeneity renders biomarker identification, which is critical for the development and administration of molecular targeted therapy, challenging when applied to a single tumor biopsy specimen. The use of circulating tumor cells or circulating tumor DNA to evaluate overall tumor heterogeneity may help resolve this problem. This article reviews previous studies of tumor heterogeneity and discusses the implications and future opportunities regarding tumor heterogeneity in HCC.

10 August 2019 in Liver International
Verified
Journal Article
Closed access
PDF file
YSYu-Yun Shao
Yu-Yun Shao
TLTsung‐Hao Liu
Tsung‐Hao Liu
CHChiun Hsu
Chiun Hsu
LLLi‐Chun Lu
Li‐Chun Lu
YSYin‐Chung Shen
Yin‐Chung Shen
CHChih-Hung Hsu
Chih-Hung Hsu

6 August 2019 in Liver Cancer
Verified
Journal Article
Open access
PDF file
LLLi-Chun Lu
Li-Chun Lu
CHChiun Hsu
Chiun Hsu
YSYu-Yun Shao
Yu-Yun Shao
YCYee Chao
Yee Chao
CYChia-Jui Yen
Chia-Jui Yen
LCLi-Tzong Chen
Li-Tzong Chen
Background and Aims: Immune checkpoint inhibitors (ICIs) exhibit significant clinical activity in patients with advanced hepatocellular carcinoma (HCC). This study explored whether tumor response to ICIs in HCC varies among different organs. Methods: We reviewed the data of patients with advanced HCC who had received ICIs. Patients with measurable diseases were enrolled. Organ-specific response criteria, adapted from RECIST 1.1 and immune-related RECIST, were used to evaluate the objective response to ICIs in tumors located in the liver, lung, lymph node, and other intra-abdominal sites. Results: Of the 75 enrolled patients with advanced HCC, 51 and 11 patients had chronic hepatitis B virus and chronic hepatitis C virus infection, respectively. Regarding ICI treatment, 58, 1, and 16 patients had undergone anti-PD-1/anti-PD-L1 monoclonal antibody (mAb) alone, anti-CTLA4 mAb alone, and anti-PD-1 mAb plus anti-CTLA4 mAb, respectively; 20 and 55 patients had received ICIs as first-line or ≥second-line therapy. The overall objective response rate (ORR) was 28.0%. In total, 58, 34, 19, and 18 patients had measurable hepatic tumors and lung, lymph node, and other intra-abdominal metastases, and the corresponding organ-specific ORRs were 22.4, 41.2, 26.3, and 38.9%, respectively. Of the 39 patients who had both hepatic and extrahepatic tumors, 12 had disease control in extrahepatic tumors while progressive disease (PD) in hepatic tumors, whereas only 4 exhibited disease control in hepatic tumors while PD in extrahepatic tumors (p = 0.046, McNemar test). Of the 16 patients with only evaluable tumors in the liver and lungs at baseline, 8 had disease control in the lungs while PD in the liver, and none experienced disease control in the liver while PD in the lungs (p = 0.005). Conclusions: The hepatic tumors of HCC may be less responsive to ICIs than extrahepatic lesions. Lung metastases responded most favorably to ICIs. The mechanisms underlying this differential response to ICIs warrant further investigation.

1 May 2019 in Journal of Hepatocellular Carcinoma
Verified
Journal Article
Open access
LLLi-Chun Lu
Li-Chun Lu
CCChun-Jung Chang
Chun-Jung Chang
CHChih-Hung Hsu
Chih-Hung Hsu
Systemic therapy for advanced hepatocellular carcinoma (HCC) has been focusing on overcoming tumor angiogenesis and immunosuppression. Myeloid-derived suppressor cells (MDSCs) promote both angiogenesis and immunosuppression in the tumor microenvironment (TME). Multiple clinical studies have demonstrated the prognostic implications of and suggested the translational significance of MDSCs in patients with HCC. In preclinical HCC models, targeting MDSCs has been shown to enhance antitumor efficacy of sorafenib or immune checkpoint inhibitors. Reversing the protumor effects of MDSCs could be achieved by depleting MDSCs, blocking MDSC trafficking and migration into TME, and inhibiting the immunosuppressive functions of MDSCs. To date, these strategies have not yet been validated to be clinically useful in patients with malignancy including HCC. Future studies should focus on identifying specific markers for human MDSCs and developing combination approaches incorporating MDSC-targeting therapy in the treatment of HCC.

20 December 2017 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
CCChun‐Jung Chang
Chun‐Jung Chang
YYYao‐Hsu Yang
Yao‐Hsu Yang
CCChiao‐Juno Chiu
Chiao‐Juno Chiu
LLLi‐Chun Lu
Li‐Chun Lu
CLChien‐Chia Liao
Chien‐Chia Liao
LCLi-Tzong Chen
Li-Tzong Chen

1 October 2016 in Cancer Letters
Verified
Journal Article
Closed access
HLHsiao-Hui Lin
Hsiao-Hui Lin
WFWen-Chi Feng
Wen-Chi Feng
LLLi-Chun Lu
Li-Chun Lu
YSYu-Yun Shao
Yu-Yun Shao
CHChih-Hung Hsu
Chih-Hung Hsu
LCLi-Tzong Chen
Li-Tzong Chen